Bisichem Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 22, 2027The maintenance fee for Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient (US 9,216,981) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Fused ring heteroaryl compounds as ALK4/5 inhibitors (US 11,932,639) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,216,981 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,932,639 | Fused ring heteroaryl compounds as ALK4/5 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,365,695 | Fused Ring Heteroaryl Compounds as RIPK1 Inhibitors In force · High confidence | In force | High confidence | |
| US 12,240,830 | Fused Ring Heteroaryl Compounds and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,741,954 | Fused Heteroaryl Hydroxamates as Sting Agonists In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending